title: Isolation and biological activity of triglycerides of the fermented mushroom of Coprinus Comatus.
abstract: BACKGROUND
  Although many physiological functions of Coprinus comatus have been reported, there has been no report on the antinociceptive activity of Coprinus comatus. Therefore, the objective of the present study is to demonstrate the production, isolation, and biological properties of triglycerides (TFC) of the fermented mushroom of Coprinus comatus.
  
  
  METHODS
  The effects of TFC on cytokines levels, total antioxidant activity, antinociceptive effects in vivo, LD50 and tactile hyperalgesia were analyzed respectively.
  
  
  RESULTS
  TFC treatment decreased the levels of cytokines and total antioxidant status (TAOS) and inhibited the acetic acid-induced abdominal constrictions in mice. In addition, TFC reduced CFA-induced tactile hyperalgesia in a dose-dependent manner and the LD50 of TFC was determined to be 400 mg/kg. However, TFC did not significantly inhibit the reaction time to thermal stimuli in the hot-plate test.
  
  
  CONCLUSIONS
  TFC showed anti-inflammatory, antioxidant, peripheral antinociceptive and antihyperalgesic activity in various models of inflammatory pain. The data suggest that TFC may be a viable treatment option for inflammatory pain.
authors.affiliation: Department of Psychology, Zhejiang Normal University, Jinhua 321004, PR China.
authors.forename: Jun
authors.initials: J
authors.lastname: Ren
authors.forename: Jin-Li
authors.initials: JL
authors.lastname: Shi
authors.forename: Chun-Chao
authors.initials: CC
authors.lastname: Han
authors.forename: Zhen-Quan
authors.initials: ZQ
authors.lastname: Liu
authors.forename: Jian-You
authors.initials: JY
authors.lastname: Guo
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced / Q000188:drug therapy; D019342:Acetic Acid; D000700:Analgesics / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D001688:Biological Products / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D003302:Coprinus / Q000737:chemistry*; D016207:Cytokines / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005285:Fermentation; D048690:Fruiting Bodies, Fungal / Q000737:chemistry; D006358:Hot Temperature; D006930:Hyperalgesia / Q000139:chemically induced / Q000188:drug therapy; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy*; D008517:Phytotherapy; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D001688:Biological Products; D016207:Cytokines; D014280:Triglycerides; D019342:Acetic Acid